Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
NCT ID: NCT04693026
Last Updated: 2021-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
150 participants
INTERVENTIONAL
2020-09-10
2021-03-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial
NCT04445935
Personalized Targeted Immunomodulation in COVID-19 ARDS
NCT06311448
Efficacy and Safety of Angiotensin II Use in Coronavirus Disease(COVID)-19 Patients With Acute Respiratory Distress Syndrome
NCT04408326
Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19
NCT04352985
Clinical Outcomes and Inflammatory Responses in Viral vs. Bacterial Sepsis
NCT06491966
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group B: Remdesivir + Tocilizumab treatment group
Remdesivir (Injectable solution) A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (\>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (\>40kg) daily following randomization.
\+
Tocilizumab (Injectable solution):
Tocilizumab I/V 8mg/Kg up to 800mg highest 12 hours apart.
Remdesivir
Remdesivir 100 IV Infusion as a lyophilized powder
Tocilizumab
Tocilizumab IV Infusion
Group A: Remdesivir + Baricitinib treatment group
Remdesivir (Injectable solution):
A loading dose of Remdesivir I/V 5mg/kg (less than 40kg) or 200mg (\>40kg) on day 1, then 2.5mg/kg (less than 40kg) or 100mg (\>40kg) daily following randomization.
\+
Baricitinib (oral tablet form):
Baricitinib tablets 4 mg/day for 2 to 4weeks
Remdesivir
Remdesivir 100 IV Infusion as a lyophilized powder
Baricitinib
Baricitinib oral tablet form
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Remdesivir
Remdesivir 100 IV Infusion as a lyophilized powder
Baricitinib
Baricitinib oral tablet form
Tocilizumab
Tocilizumab IV Infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First affiliated Hospital Xi'an Jiaoting University
UNKNOWN
M Abdur Rahim Medical College and Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abu Taiub Mohammed Mohiuddin Chowdhury
Resident
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD
Role: STUDY_CHAIR
First Affiliated Hospital Xi'an Jiaotong University
Akter Kamal, MD, PhD
Role: STUDY_DIRECTOR
M Abdur Rahim Medical College and Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
M. Abdur Rahim Medical College Hospital
Dinajpur, , Bangladesh
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M.A.R.M.C.D./2020/2637
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.